METIS TECHBIO-P (07666) experienced a significant rally, climbing more than 33% during trading. As of the latest update, the stock was up 31.74% at HK$15.44, with trading turnover reaching HK$87.6427 million.
On the news front, August 19 marked a pivotal moment when Moderna and Merck announced that their jointly developed melanoma mRNA cancer vaccine had achieved its primary endpoint in Phase III clinical trials. This milestone positions it as the world's first clinically validated mRNA therapeutic cancer vaccine, demonstrating the feasibility of mRNA technology for cancer treatment and its commercial potential. The announcement propelled Moderna's stock price to surge by 176.97%, with market expectations pointing toward a potential revaluation of the domestic mRNA technology sector.
Notably, METIS TECHBIO-P leverages its AI-powered end-to-end NanoForge platform, which integrates mRNA design, LNP delivery, and protein engineering capabilities. The company possesses both mRNA tumor vaccine development expertise and LNP delivery "picks-and-shovels" capabilities. Its MTS-107 pipeline represents a significant asset in oncology treatment, utilizing spleen-targeted LNP delivery of mRNA combined with E6/E7 dual antigens and immune activation mechanisms to explore HPV-related cancer therapies. Meanwhile, MTS-105 employs liver-targeted LNP technology, enabling hepatocytes to produce and secrete TCE in situ within the body, which then migrates to tumor tissues for therapeutic effect.